Daily Cardiology Research Analysis
Three papers stand out today: a large U.S. registry shows controlled hypothermic donor heart preservation (SCTS) improves 2-year survival and reduces early graft dysfunction after transplant; a massive prospective Chinese cohort refines non–HDL-cholesterol targets by baseline risk with strong associations to ASCVD and mortality; and a cluster-randomized trial suggests Guanxinning tablets plus aspirin may lower post-PCI events without increasing major bleeding.
Summary
Three papers stand out today: a large U.S. registry shows controlled hypothermic donor heart preservation (SCTS) improves 2-year survival and reduces early graft dysfunction after transplant; a massive prospective Chinese cohort refines non–HDL-cholesterol targets by baseline risk with strong associations to ASCVD and mortality; and a cluster-randomized trial suggests Guanxinning tablets plus aspirin may lower post-PCI events without increasing major bleeding.
Research Themes
- Transplant organ preservation and post-transplant outcomes
- Risk-factor thresholds for ASCVD prevention
- Adjunct antithrombotic strategies after PCI
Selected Articles
1. 7Improved 2-year Heart Transplant Survival with Moderate Hypothermic Donor Heart Preservation in the GUARDIAN Heart Registry.
In a 1,261-patient U.S. registry, controlled hypothermic preservation with SCTS reduced severe primary graft dysfunction and right ventricular dysfunction and improved 2-year survival compared with ice storage, remaining significant after propensity matching. This is the first preservation modality to demonstrate a survival advantage post–heart transplant.
Impact: Demonstrates a clinically meaningful survival benefit linked to an implementable preservation strategy in heart transplantation, a field where early graft dysfunction remains a major determinant of outcomes.
Clinical Implications: Transplant programs may consider adopting controlled hypothermic SCTS for donor hearts to reduce severe PGD/RVD and improve medium-term survival; guidelines and procurement protocols may need revision to incorporate controlled hypothermia.
Key Findings
- SCTS was associated with lower severe PGD (10.8% vs 6.8%, p=0.015) and severe RVD (9.9% vs 6.1%, p=0.022) versus ice storage.
- SCTS independently predicted lower odds of severe PGD (OR 0.60) and severe RVD (OR 0.75).
- In propensity-matched analyses, 2-year mortality was reduced with SCTS (10.5% vs 5.7%, p=0.042), with higher Kaplan–Meier survival probability (p=0.022).
Methodological Strengths
- Large, contemporary real-world registry with propensity matching and multivariable modeling
- Clinically hard endpoints including severe PGD, severe RVD, and 2-year mortality
Limitations
- Observational, non-randomized design with potential residual confounding
- Technique adoption and center-level practices may influence outcomes and generalizability
Future Directions: Confirmatory randomized or quasi-experimental studies, cost-effectiveness analyses, and evaluations in extended-criteria donors and longer follow-up are warranted.
BACKGROUND: Multiple advanced preservation technologies are now available and have demonstrated utility in organ assessment and preservation. The Paragonix SherpaPak® Cardiac Transport System (SCTS) has become the most common method of static preservation demonstrating superior outcomes to historic ice storage. To date, no preservation method has reported improved post-transplant survival. METHODS: Data from the GUARDIAN-Heart Registry, the largest real-world registry focused on organ preservation, were analyzed to quantify post-transplant clinical outcomes and survival in transplant cases utilizing ice cooler storage or moderate hypothermic preservation using SCTS. The independent contributions of organ preservation method on outcomes, including severe primary graft dysfunction (PGD), right ventricular dysfunction (RVD), and mortality, were analyzed using propensity matching and logistic regression. RESULTS: Among 1,261 US adult heart transplants performed between October 2015 - January 2024, SCTS utilization was associated with significant reductions in incidence of severe PGD (Ice 10.8% vs. SCTS 6.8%, p=0.015) and severe RVD (Ice 9.9% vs. SCTS 6.1%, p=0.022). SCTS use was identified as an independent predictor of severe PGD (Odds Ratio = 0.60, p=0.012) and severe RVD (OR = 0.75, p=0.047). In the propensity-matched cohort, SCTS utilization was associated with a significant reduction in mortality after 2 years (Ice 10.5% vs. SCTS 5.7%, p=0.042), and the Kaplan-Meier survival probability over 2 years was significantly higher in the SCTS cohort (p=0.022). CONCLUSIONS: Moderate, controlled hypothermic preservation using SCTS significantly improves post-transplant outcomes and 2-year survival. This is the first study of any advanced heart preservation modality to demonstrate a significant impact on transplant survival.
2. Association of non-high-density lipoprotein cholesterol with atherosclerotic cardiovascular disease and all-cause mortality in Chinese populations with different baseline risks: A prospective cohort study.
Across 183,224 participants stratified by baseline risk, lower non–HDL-C thresholds (<140 mg/dL for low risk, <120 mg/dL for primary prevention, <100 mg/dL for secondary prevention) were associated with lower ASCVD and mortality. Sustained low non–HDL-C conferred additional risk reduction, especially for ASCVD in low/primary prevention and mortality in secondary prevention.
Impact: Provides risk-stratified, actionable non–HDL-C thresholds and underscores the importance of sustained lowering for ASCVD prevention, informing lipid management beyond LDL-centric targets.
Clinical Implications: Consider adopting lower non–HDL-C targets tailored to baseline risk (<140, <120, <100 mg/dL) and prioritizing sustained reduction over time in preventive cardiology, alongside LDL-C goals.
Key Findings
- Risk-stratified non–HDL-C thresholds associated with lower ASCVD and all-cause mortality: <140 mg/dL (low risk), <120 mg/dL (primary prevention), <100 mg/dL (secondary prevention).
- Sustained low non–HDL-C was linked to 43% lower ASCVD risk in low-risk and 27% in primary prevention; in secondary prevention, it corresponded to a 25% lower all-cause mortality.
- Time-varying Cox models and repeated measures strengthened inference across 183,224 participants.
Methodological Strengths
- Very large, prospectively followed cohort with risk stratification by Framingham score
- Use of time-varying Cox models and repeated non–HDL-C measurements to assess sustained effects
Limitations
- Observational design limits causal inference; potential residual confounding
- Generalizability outside Chinese populations and clinical implementation details require validation
Future Directions: Intervention trials testing risk-tiered non–HDL-C targets, evaluation across diverse populations, and integration with apoB-based strategies.
BACKGROUND: This study, for the first time, stratified a larger sample size of participants according to the Framingham Risk Score and applied a fine-grained classification of non-high-density lipoprotein cholesterol (non-HDL-C) in 20 mg/dL increments, aiming to further analyze the associations of baseline non-HDL-C and its changes with atherosclerotic cardiovascular disease (ASCVD) and all-cause mortality across different baseline risk populations. METHODS: The study included 90,072 low-risk individuals, 77,499 primary prevention individuals, and 15,653 secondary prevention individuals. Using time-varying Cox proportional hazards regression models, we assessed the association of non-HDL-C levels with the risks of ASCVD and all-cause mortality across different baseline risk populations. Furthermore, based on non-HDL-C levels in 2 consecutive measurements, we evaluated the association of changes in non-HDL-C with the risks of ASCVD and all-cause mortality. RESULTS: This study found that non-HDL-C levels below 140 mg/dL in low-risk populations, below 120 mg/dL in primary prevention populations, and below 100 mg/dL in secondary prevention populations were significantly associated with a reduced risk of ASCVD and all-cause mortality. Furthermore, sustained lower non-HDL-C was associated with a 43% reduced risk of ASCVD in low-risk populations and a 27% reduced risk in primary prevention populations, whereas in secondary prevention populations it corresponded to a 25% reduced risk of all-cause mortality. CONCLUSIONS: As baseline risk levels increase, lower non-HDL-C levels are significantly associated with reduced risks of ASCVD and all-cause mortality. Moreover, sustained lower non-HDL-C levels are associated with a significant decrease in ASCVD and all-cause mortality risks across different baseline risk populations.
3. Guanxinning tablets plus aspirin versus aspirin monotherapy to reduce cardiovascular events after percutaneous coronary intervention: A cluster-randomized controlled trial (GAP trial).
In 3,586 post-PCI patients stepping down from ≥12 months of DAPT, adding Guanxinning to aspirin reduced a composite of cardiovascular events (HR 0.79) without increasing major bleeding over a median 23 months. Benefits were driven by fewer revascularizations and rehospitalizations for unstable angina.
Impact: Provides randomized evidence for an adjunct strategy during transition off DAPT that may lower ischemic events without excess bleeding, addressing a common clinical dilemma.
Clinical Implications: For stable post-PCI patients transitioning to aspirin monotherapy, adding GXNT may be considered where available and appropriate, with attention to regulatory status, quality control, and patient preference; not a substitute for guideline-directed DAPT in high-risk early phases.
Key Findings
- Cluster-randomized trial across 63 hospitals: GXNT + aspirin reduced the composite primary endpoint versus aspirin alone (11.0% vs 13.2%; adjusted HR 0.79, 95% CI 0.63–0.98).
- Lower rates of revascularization (3.8% vs 4.7%) and rehospitalization for unstable angina (7.0% vs 9.7%) with GXNT.
- Major bleeding events were rare and similar between groups over a median 23-month follow-up.
Methodological Strengths
- Cluster-randomized design with blinded outcome assessment and intention-to-treat analysis accounting for ICC
- Large, multi-center pragmatic trial reflecting real-world transition off DAPT
Limitations
- Open-label design and composite endpoint including softer outcomes may introduce bias
- Conducted in China with a traditional medicine intervention; generalizability, product standardization, and regulatory considerations apply
Future Directions: Double-blind, placebo-controlled trials outside China, pharmacovigilance and interaction studies, and health-economic evaluations to define positioning relative to shortened DAPT strategies.
BACKGROUND: Prolonged dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) lowers thrombotic risk but increases bleeding, creating a therapeutic dilemma. Guanxinning tablets (GXNT), a traditional Chinese medicine with antithrombotic and cardioprotective effects, may offer an alternative strategy. PURPOSE: To evaluate whether GXNT combined with aspirin reduces cardiovascular events without increasing bleeding in patients transitioning from DAPT to aspirin monotherapy after PCI. STUDY DESIGN: An open-label, cluster-randomized controlled trial conducted in 63 tertiary hospitals in China between March 2017 and December 2018. METHODS: A total of 3586 patients with coronary heart disease (CHD) who had completed at least 12 months of DAPT following PCI were enrolled. Hospitals and participants were randomized in a 2:1 ratio to receive GXNT plus aspirin or aspirin alone for 12 months, followed by 12 months of additional follow-up. The primary endpoint was a composite of cardiovascular death, non-fatal myocardial infarction, stent thrombosis, revascularization, ischemic stroke, and rehospitalization for unstable angina. Outcome assessors and data analysts were blinded to treatment allocation. The intention-to-treat analysis principle was adopted, and ICC were accounted for in the statistical analysis. RESULTS: Of the participants, 2389 received GXNT plus aspirin and 1197 received aspirin alone. After a median follow-up of 23 months, GXNT significantly reduced the primary outcome (11.0 % vs. 13.2 %; adjusted hazard ratio [HR] 0.79, 95 % confidence interval [CI] 0.63-0.98). Rates of revascularization (3.8 % vs 4.7 %) and rehospitalization for unstable angina (7.0 % vs 9.7 %) were also lower in the GXNT group. Major bleeding events were rare and similar across groups. CONCLUSION: GXNT combined with aspirin reduced adverse cardiovascular events after PCI without increasing bleeding, supporting its potential as an alternative to prolonged DAPT.